Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 6
Submit an article Journal homepage
81
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493)

Peter H. WiernikBeth Israel Medical Center and St. Lukes-Roosevelt Hospital Center, New York, NY, USACorrespondence[email protected]
,
Hailun LiDana Farber Cancer Institute, Boston, MA, USA
,
Edie WellerDana Farber Cancer Institute, Boston, MA, USA
,
Howard S. HochsterNew York University School of Medicine, New York, NY, USA
,
Sandra J. HorningStanford University, Stanford, CA, USA
,
Tipu NazeerAlbany Medical College, Albany, NY, USA
,
Leo I. GordonNorthwestern University, Chicago, IL, USA
,
Thomas M. HabermannMayo Clinic, Rochester, MN, USA
,
Carl J. Minniti JrThe Minniti Center for Oncology/Hematology, Mickleton, NJ, USA
,
Gary R. ShapiroAurora Sinai Medical Center, Milwaukee, WI, USA
&
Peter A. CassilethUniversity of Miami, Miami, FL, USA
 show all
Pages 1137-1142 | Received 13 Oct 2011, Accepted 17 Nov 2011, Published online: 11 Jan 2012

References

  • Hsiang YH, Hertzberg R, Hecht S, . Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873–14878.
  • Hsiang YH, Liu LF. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;49:5077–5082.
  • Wang JC. DNA topoisomerases. Ann Rev Biochem 1985;54:665–697.
  • Creemers GJ, Bolis G, Gore M, . Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer; results of a large European phase II study. J Clin Oncol 1996;14:3056–3061.
  • ten Bokkel Huinik W, Gore M, Carmichael J, . Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183–2193.
  • Hochster H, Liebes L, Speyer J, . Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:533–559.
  • Hochster H, Liebes L, Speyer J, . Effect of prolonged topotecan infusion on topoisomerase I levels: a phase I and pharmacodynamic study. Clin Cancer Res 1997;3:1245–1252.
  • Hochster H, Wadler S, Runowicz C, . Activity and pharmacodyamics of 21-day topotecan infusion in ovarian cancer patients previously treated with platinum-based chemotherapy. J Clin Oncol 1999;17:2553–2561.
  • Oken MM, Creech RH, Tormey DC, . Toxicity and response criteria of the ECOG. Am J Clin Oncol 1982;5:649–655.
  • Kaplan EL, Meier P. Non-parametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457–481.
  • Wiernik PH, Lossos IS, Tuscano JM, . Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952–4957.
  • Witzig TE, Vose JM, Zinzani PL, . An international phase II study of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622–1627.
  • Coiffier B, Haioun C, Ketterer N, . Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–1932.
  • Rummel MJ, Gregory SA. Bendamustine's emerging role in the management of lymphoid malignancies. Semin Hematol 2011;48 (Suppl. 1):S24–S36.
  • Goy A, Younes A, Mclaughlin P, . Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667–675.
  • Beran M, Kantarjian HM. Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies. Ann NY Acad Sci 2000;922:247–259.
  • Kraut EH, Balcerzak SP, Young D, . A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study. Cancer Invest 2002;20:174–179.
  • Younes A, Preti HA, Hagemeister FB, . Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001;12:923–927.
  • Kancherla RR, Nair JS, Ahmed T, . Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response. Cancer 2001;91:463–471.
  • Beran M, Kantarjian H, O'Brien S, . Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996;88: 2473–2479.
  • Beran M, Estey E, O'Brien S, . Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999;17: 2819–2830.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.